Survival: | 4.9 months |
Toxicity Grade: | 5 |
Treatments: | Chemotherapy |
Drugs: | Xeloda |
Country: | United States |
City/State/Province: | Columbus, Ohio |
Hospital: | Ohio State University Comprehensive Cancer Center |
Journal: | Link |
Date: | 5/2004 |
Description: |
Patients: This Phase II study involved 27 patients with malignant mesothelioma. Treatment: The treatment consisted of the administration of the chemotherapy drug, capecitabine (xeloda), Toxicity: One patient died of treatment related diarrhea, dehydration, fever and neutropenia. Other grade 3-4 toxicities included hematologic, hypertension, fatigue, dermatological, anorexia, dehydration, diarrhea, nausea, stomatitis/pharyngitis, infection, and pain. Results: Median survival was 4.9 months. Correspondence: Gregory A. Otterson, MD |